Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies
Rondy M., Kissling E., Emborg HD., Gherasim A., Pebody R., Trebbien R., Pozo F., Larrauri A., McMenamin J., Valenciano M., Kaic B., Filipovic SK., Visekruna-Vucina V., Novosel IP., Lovric Z., Petrović G., Krause TG., Fische TK., Lina B., Falchi A., Vilcu AM., Souty C., Blanchon T., van der Werf S., Enouf V., Behillil S., Valette M., Bernard-Stoecklin S., Lévy-Bruhl D., Launay O., Loulergue P., Lenzi N., Lesieur Z., L’Honneur AS., Galtier F., Agostini C., Serrand C., Merle C., Foulongne V., Vanhems P., Lainé F., Lagathu G., Carrat F., Buda S., Preuss U., Prahm K., Schweiger B., Wedde M., Heider A., Martin M., Biere B., Duerrwald R., Domegan L., Coughlan L., O’Donnell J., Joyce M., Collins C., Dunford L., Moran J., Tuite G., Duffy M., Connell J., de Gascun C., Rizzo C., Bella A., Alfonsi V., Castrucci MR., Puzelli S., Pagani E., Ghisetti V., Pariani E., Baldanti F., Palù G., D’Agaro P., Ansaldi F., Affanni P., Rossolini GM., Camilloni B., Bagnarelli P., Sanguinetti M., Atripaldi L., Chironna M., Serra C., Vitale F., Germinario C., Orsi A., Manini I., Montomoli E., Napoli C., Orsi GB., Casado I., Castilla J., Fernandino L., Martínez-Baz I., Ezpeleta G., Navascués A., Pérez-García A., Aguinaga A.
© the authors, 2018. Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.